Pancreatic Cancer Research

ResearcherKumamoto UniversityActive in the last 2 years

Hiromitsu Hayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1832-4287; OpenAlex author ID A5017859885. Sources: OpenAlex.

Their work

Papers
43 (first author 14, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
95
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 9 papers · 2022: 3 papers · 2023: 7 papers · 2024: 2 papers · 2025: 2 papers · 2026: 11 papers

Papers 43

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for Pancreatic Cancer. First author DOI 10.1002/ags3.70297↗
  3. High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection. Co-author DOI 10.1002/jhbp.70032↗
  4. A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. Co-author DOI 10.1007/s12328-025-02256-2↗
  5. A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy. Co-author DOI 10.1007/s12328-026-02359-4↗
  6. The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreatectomy. First author DOI 10.1016/j.pan.2026.04.008↗
  7. Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… First author DOI 10.1097/mpa.0000000000002641↗
  8. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  9. Proinsulin Promotes Tumor Development in the PANC-1 Pancreatic Adenocarcinoma Cell Line. Co-author DOI 10.21873/anticanres.18130↗
  10. Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.18442↗
  11. A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab. Co-author DOI 10.70352/scrj.cr.26-0273↗
  12. Serum Mac2-binding protein glycosylated isomer (M2BPGi) as a prognostic biomarker in pancreatic ductal adenocarcinoma: iCAFs-derived M2BPGi drives tumor invasi… Co-author DOI 10.1007/s00535-024-02195-8↗
  13. Molecular Alterations Influencing the Prognostic Outcome in Small Pancreatic Cancer (≤2 cm). First author DOI 10.1097/mpa.0000000000002430↗
  14. Impairment of perioperative activities of daily living is associated with poor prognosis following pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00423-024-03478-7↗
  15. Prognostic impact of tumor marker kinetics and normalization during neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.21037/hbsn-23-662↗
  16. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  17. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  18. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… First author DOI 10.1038/s41416-022-02106-9↗
  19. The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. Co-author DOI 10.1097/mpa.0000000000002210↗
  20. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.1172/jci.insight.163022↗
  21. Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers15020498↗
  22. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… First author PMID 37293171↗
  23. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.tranon.2022.101533↗
  24. Survival Impact of Perioperative Red Blood Cell Transfusion During Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Propensity Score Matchin… Co-author DOI 10.1097/mpa.0000000000001997↗
  25. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1245/s10434-022-11500-9↗
  26. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12436↗
  27. Frailty is associated with poor prognosis after resection for pancreatic cancer. First author DOI 10.1007/s10147-021-01983-z↗
  28. Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.09.007↗
  29. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study. First author DOI 10.1245/s10434-020-09022-3↗
  30. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09383-9↗
  31. Precision surgery with the genetic assessment for operable pancreatic cancer beyond the radiological assessment alone. Co-author DOI 10.21037/hbsn-20-820↗
  32. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15071↗
  33. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.700315↗
  34. Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma. Co-author DOI 10.3748/wjg.v27.i43.7480↗
  35. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients underg… Co-author DOI 10.1007/s00595-019-01866-x↗
  36. Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. First author DOI 10.1097/mpa.0000000000001622↗
  37. ASO Author Reflections: Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single Institutio… First author DOI 10.1245/s10434-020-09039-8↗
  38. Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/invivo.12111↗
  39. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. First author DOI 10.1007/s12328-019-00965-z↗
  40. Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07266-2↗
  41. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Co-author DOI 10.1007/s00595-015-1238-8↗
  42. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Co-author DOI 10.1111/cas.12732↗
  43. Hepatobiliary and pancreatic: sigmoidal mesenterial lymph node metastasis from pancreatic cancer. Co-author DOI 10.1111/jgh.12807↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirohisa Okabe · 15 shared papers, 2015–2026 · strength 3.09
  2. Yuki Kitano · 12 shared papers, 2020–2026 · strength 2.82
  3. Shigeki Nakagawa · 15 shared papers, 2015–2026 · strength 2.68
  4. Masaaki Iwatsuki · 9 shared papers, 2026 · strength 2.57
  5. Rumi Itoyama · 13 shared papers, 2014–2026 · strength 1.99
  6. Zhao Liu · 11 shared papers, 2020–2026 · strength 1.91
  7. Katsunori Imai · 16 shared papers, 2015–2023 · strength 1.87
  8. Hideo Baba · 15 shared papers, 2014–2024 · strength 1.82
  9. Tatsunori Miyata · 11 shared papers, 2020–2026 · strength 1.79
  10. Norio Uemura · 12 shared papers, 2020–2026 · strength 1.79
  11. Kosuke Mima · 10 shared papers, 2021–2026 · strength 1.73
  12. Takanobu Yamao · 9 shared papers, 2019–2026 · strength 1.61
  13. Shinsei Yumoto · 5 shared papers, 2026 · strength 1.36
  14. Toru Takematsu · 5 shared papers, 2020–2026 · strength 1.19
  15. Takashi Matsumoto · 5 shared papers, 2021–2026 · strength 0.97
  16. Takayoshi Kaida · 7 shared papers, 2016–2024 · strength 0.96
  17. Kazuki Matsumura · 7 shared papers, 2020–2023 · strength 0.93
  18. Yosuke Nakao · 7 shared papers, 2019–2025 · strength 0.86
  19. Hiroki Sato · 5 shared papers, 2021–2023 · strength 0.80
  20. Hideo Baba · 5 shared papers, 2020–2023 · strength 0.79
  21. Yuki Adachi · 3 shared papers, 2024–2026 · strength 0.74
  22. Fumimasa Kitamura · 6 shared papers, 2020–2023 · strength 0.69
  23. Hideo Baba · 4 shared papers, 2021–2023 · strength 0.67
  24. Takatsugu Ishimoto · 4 shared papers, 2021–2025 · strength 0.56
  25. Yasuhito Tanaka · 2 shared papers, 2025–2026 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.